Why AnaptysBio Trounced the Market on Thursday

1 min read

AnaptysBio (NASDAQ: ANAB) rose by just over 11% on Thursday, as a high-profile bank has become more optimistic on the stock, to put it lightly.

J.P. Morgan analyst Anupam Rama upgraded his recommendation on AnaptysBio stock. In his estimation, it’s now overweight (i.e., buy), from the previous underweight (sell). The analyst also more than doubled his price target on the shares to $40; it was formerly $19.

Image source: Getty Images.

Continue reading

Leave a Reply

Your email address will not be published.

Previous Story

Investors Swipe Right on Bumble IPO

Next Story

Verisign Inc (VRSN) Q4 2020 Earnings Call Transcript

Latest from Blog